MONMOUTH JUNCTION, N.J. - Oct. 4, 2017 - PRLog -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their hemoglobin depletion technology for improving western blot analysis from whole blood protein. The citation is:
Chalásová, Katarína, et al. “Transketolase Activity but not Thiamine Membrane Transport Change in Response to Hyperglycaemia and Kidney Dysfunction.”
Diabetic kidney disease, a common complication of both type 1 and type 2 diabetes, is associated with significant morbidity and mortality, and represents the most common cause of chronic kidney disease. The study hypothesized that protective pentose phosphate pathway action in diabetes might be compromised by limited intracellular availability of an active transketolase cofactor thiamine diphosphate (TDP). To evaluate the levels of thiamine tranporter proteins in whole blood, the article states “For protein isolation, whole blood aliquots were lysed with water and haemoglobin was removed using HemogloBind™
“Because of the large amount of hemoglobin in whole blood, here is another article demonstrating that HemogloBind™
For more information on HemogloBind™
http://www.biotechsupportgroup.com/
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™
Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com
